Poolbeg Pharma (POLB) Investor presentation - June 2024

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD and Chief Business Officer, David Allmond present an overview of their current programmes and opportunities, focussing on POLB 001, their oral delivery platforms, exclusive option agreement and their AI-powered research using human viral challenge data, followed by a Q&A session.

Jeremy Skillington PhD, Chief Executive Officer
00:16 - Introduction
03:06 - Programmes
04:08 - 2024 highlights

David Allmond, Chief Business Officer
05:03 - POLB 001 & CRS
08:01 - POLB 001's efficacy
10:15 - POLB 001 Market Opportunity
14:17 - POLB 001 support
16:12 - Topical PTX & Behçet's Disease
18:36 - Topical PTX 12 month option
20:29 - Topical PTX Phase 2 trial

Jeremy Skillington PhD, Chief Executive Officer
22:05 - Topical PTX outlook
22:48 - Oral delivery platform
25:02 - Artificial Intelligence programmes
28:13 - Investment case

29:30 - Q&A

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

For more information, please go to www.poolbegpharma.com  or follow on Twitter and LinkedIn @PoolbegPharma.